ArgentinaStand No: 101C60
AMEGA Biotech is focused on biosimilar products development and manufacturing, from cell line engineering and drug substance to drug product. Our global presence includes Turkey, MENA region and over 20 countries. AMEGA Biotech builds and fosters worldwide solid strategic alliances and partnerships for co-development, technology transfer, distribution and clinical trials.
United StatesStand No: 90C90
Amneal Pharmaceuticals LLC, a privately-held company with US headquarters in New Jersey and international headquarters in Switzerland, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia, Australia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.
RussiaStand No: 62B31
BIOCAD is fully integrated pharmaceutical company, excels at full-cycle drug discovery and development, large-scale manufacturing of therapeutics for the treatment cancer and autoimmune disorders. Having a number of mAb biosimilars on the market, BIOCAD has become a top manufacture of high value chemical APIs – glatiramer acetate, pemetrexed and others.
IndiaStand No: 80J80
Established in 1978, Biocon Limited, is India's largest, and Asia's leading, biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. We develop, manufacture and deliver a rich portfolio of Small Molecules APIs & Formulations and Complex Biologics - both Novels and Biosimilars - including MAbs, rh-insulin& Insulin Analogs. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG and India's first biologic BioMAb-EGFR; for head and neck cancer. It has now successfully developed its second novel biologic Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, being introduced as Alzumab; for psoriasis in India, in 2013.
ArgentinaStand No: 101A66
Biosidus, is an Argentina-based company pioneer in biotechnology, which for three decades have been developing and producing top quality recombinant proteins. Since the launch of epoetin in 1990, Biosidus has increased its presence worldwide across Latin America, Eastern Europe, Africa, Middle East and Asia. Today, we are selling our products in more 45 countries worldwide. This also includes our own presence in strategic markets through JVs. Biosidus's portfolio consists of eight key recombinant human proteins across the therapeutic divisions of Nephrology, Hematology, Multiple Sclerosis, Endocrinology, Oncology and Hepatitis: epoetin, filgrastim, lenograstim, interferon beta 1a, somatropin, teriparatide, interferon alfa 2a and interferon alfa 2b. Together with this, we have the following products in different stages of development: peginterferon alfa 2a, pegfilgrastim, interferon beta 1a (30 mcg intramuscular), interferon beta 1b and agalsidase. Recently, we have enlarged our portfolio by including generic products (small molecules) to our Onco-Hematology, Oncology and Immunosuppressive areas...
BrazilStand No: 90D62
Blau Farmacêutica is a Brazilian pharmaceutical company, leader in Latin America, present in Argentina, Chile, Colombia, Peru and Uruguay. The company is a pioneer in highly complex medicines, specialized in biotechnology, oncology, nephrology, hematology, infectious diseases and others. Celebrating 30 years, Blau Farmacêutica is pleased to show your strength, competence and technique experienced in developing more than 100 different products. Blau's portfolio includes products, which are available for a wide range of applications. The excellence of these products, are a proof of the company's devotion to customer satisfaction and the well-being of its consumers.
SpainStand No: 90C91
Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich, Germany. The Company develops, manufactures and commercialises high-quality biosimilars for oncology and inflammatory diseases to address the growing need for affordable therapies. An expert team specialised in biosimilars is conducting product development, clinical studies, manufacturing and quality control in Europe, according to the highest quality standards. Cinfa Biotech's lead product candidate is B12019, a biosimilar version of Neulasta® (pegfilgrastim) used to treat chemotherapy-induced neutropenia. The Marketing Authorisation Application for B12019 for the European Union was accepted for review by the EMA in September 2017. The clinical program was based on scientific advice from EMA and included two studies, which confirmed the analytical and biofunctional similarity of B12019 and Neulasta® in highly sensitive clinical study settings. Comparative analytical and functional data are currently being generated for B12019 regarding EU-authorised and US-licensed reference product. A briefing package for FDA will be...
United KingdomStand No: 41M02
Contract Manufacturing Excellence with Cobra Biologics Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing a comprehensive biologics and pharmaceuticals service offering. Our multi-functional and experienced project teams nurture customers' products through to clinical and commercial manufacture within three GMP approved facilities. Expertise Cobra is a contract development and manufacturing organisation (CDMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply. For Gene Therapy products we can produce DNA, Adenovirus, AAV, Lentivirus and other virus material for both clinical and commercial supply. Cobra provides manufacturing technologies, platforms and solutions for gene therapy products. For our AAV and Lentivirus customers we have developed a High Quality DNA platform process to enable the rapid supply of small quantities of DNA material for the production...
TurkeyStand No: 90G75
ILKO is a subsidiary of Selcuklu Holding which has strong institutions across various economic sectors. ILKO was founded by pharmacist Mustafa Öncel who was active in the pharmaceutical industry since 1973, resulting with successful sale of the previous pharma company to international partnerships, in 2006. Öncel family has invested again in pharmaceutical industry with about their 50 years of experience by young company, ILKO. ILKO has started its business activities in 2012. As of 2017, ILKO has over 600 employees with its own licensed 47 products within 185 different forms in different therapeutic areas like; Central Nervous system, Respiratory System, Alimentary and Metabolism, Anti-infectives, Musco-Skeletal System, Cardiovascular System and Heamatology. ILKO's production facilities have been approved for EU-GMP certificate by MHRA–UK and through its wide portfolio ILKO has business to international markets in several countries. The production facility of the company is the largest pharmaceutical manufacturing investment in Anatolia. The...
FranceStand No: 42A10
Mapi Group has over 40 years of experience supporting Life-Science companies in utilizing Patient Reported Outcomes measures, Value communications and Health Economics and Outcomes Research, Strategic Regulatory Services, Pharmacovigilance, Health Research, Language Services, and gathering Real-World Evidence on Pharmaceuticals, Biologicals, and Medical Devices. Visit http://www.mapigroup.com for more information.
MalaysiaStand No: 91H63
Pharmaniaga Berhad is a member of Boustead Group of Companies which is of a Government Linked Company status listed in the Main Board of Bursa Malaysia. The Pharmaniaga Group's core businesses are generic pharmaceuticals manufacturing, research and development, marketing and sales, warehousing and distribution of pharmaceutical and medical products as well as supply, trading and installation of medical and hospital equipment. The capabilities of its two manufacturing plants allow the Pharmaniaga Group to deliver on its commitment to bring quality, affordable medicines to the community. One plant is equipped with production facilities for solids, liquids, "cephalosporin dry powder" injectables and "beta-lectam" antibiotics, together with state-of-the-art quality control and assurance laboratories, and modern research and development facilities; while the other plant is poised to be the low cost supplier of Small Volume Injectables (SVI) products in vials and ampoules to the regulated markets of Europe and the US. The Group's manufacturing...
SwitzerlandStand No: 42B30
Our Life Science Services provide analytical, bioanalytical and clinical trial testing capabilities, along with process management, that enable pharmaceuticals to swiftly reach those that need them with minimal cost and maximum safety. We partner with the pharmaceutical, biopharmaceutical, biotechnology, medical device and healthcare-related industries to provide a wide range of essential services.
TaiwanStand No: 101A70
Founded in California, USA, in 2005, SUNTEC has steadily developed as a leading multinational pharmaceutical company, with a prestigious reputation for high quality. As a branded pharmaceuticals business, SUNTEC's business is closely aligned with market needs worldwide. Today, SUNTEC is focusing on providing a broad range of biosimilars, most recently available generic drugs, and MNC new drugs. SUNTEC is committed to provide access to safe, effective and affordable medicines the people who need them.
ChinaStand No: 101C74
AMOYTOP BIOTECH, the leading manufacturer of recombinant bio-pharmaceutical products in China with cGMP, produces Molgramostim, Filgrastim, Oprelvekin, Interferon-alfa-2a, Interferon-alfa-2b, Interferon gamma, Interleukin-2 and Somatropin, and provides bio-reagents, such as Interleukin-4, TNF, and recombinant human SOD. AMOYTOP is also developing Y-shaped branch PEG Drug Delivery Technology in: YPeg-filgrastim, YPeginterferon-alfa-2a, YPeg-interferon-alfa-2b, YPeg-somatropin and YPeg-EPO. AMOYTOP, the first and largest company to launch domestic Molgramostim in China, is Molgramostim Reference Standard supplier to National Institutes for Food and Drug Control (NIFDC), China. AMOYTOP also provides service as Contract manufacturer and Contract research according to different requirements.